Prime Medicine Investor Relations Material

Prime Medicine, Inc. is a biotechnology company specializing in next-generation gene editing technologies aimed at developing curative therapies for a broad range of genetic diseases. The company utilizes its proprietary Prime Editing platform, a highly precise and versatile method of correcting disease-causing mutations in DNA, targeting nearly 90% of known genetic mutations. Prime Medicine's therapeutic focus includes areas like hematology, immunology, liver, ocular, and neuromuscular diseases. The company is headquartered in Cambridge, Massachussetts, and its shares are listed on the NASDAQ.